Equities research analysts at Bank of America assumed coverage on shares of Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) in a research report issued on Thursday, Briefing.com reports. The firm set a "buy" rating and a $47.00 price target on the stock. Bank of America's target price would indicate a potential upside of 56.04% from the stock's current price.
A number of other equities research analysts also recently issued reports on the stock. Leerink Partners increased their price target on shares of Viridian Therapeutics from $50.00 to $54.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Wedbush boosted their price objective on shares of Viridian Therapeutics from $41.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Wells Fargo & Company boosted their price objective on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Thursday, November 5th. Wall Street Zen raised shares of Viridian Therapeutics from a "strong sell" rating to a "hold" rating in a report on Saturday, November 7th. Finally, HC Wainwright increased their target price on shares of Viridian Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.46.
Read Our Latest Analysis on VRDN
Viridian Therapeutics Stock Performance
NASDAQ:VRDN opened at $30.12 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 14.46 and a current ratio of 14.46. Viridian Therapeutics has a 52-week low of $13.18 and a 52-week high of $34.29. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of -7.84 and a beta of 1.07. The business's fifty day moving average is $23.17 and its 200 day moving average is $21.70.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.21. The business had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. Research analysts predict that Viridian Therapeutics will post -3.64 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. KBC Group NV bought a new stake in Viridian Therapeutics during the first quarter valued at approximately $34,000. Integrated Wealth Concepts LLC bought a new position in shares of Viridian Therapeutics in the 2nd quarter worth $33,000. State of Wyoming purchased a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at $43,000. Fulcrum Asset Management LLP purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at $97,000. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at $216,000.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company's pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.